{"nctId":"NCT01411774","briefTitle":"D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)","startDateStruct":{"date":"2011-06"},"conditions":["Obsessive-compulsive Disorder"],"count":142,"armGroups":[{"label":"Cognitive-behavioral therapy plus pill placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Cognitive-behavioral therapy","Drug: Pill placebo"]},{"label":"Cognitive-behavioral Therapy plus d-cycloserine","type":"EXPERIMENTAL","interventionNames":["Behavioral: Cognitive-behavioral therapy","Drug: d-cycloserine"]}],"interventions":[{"name":"Cognitive-behavioral therapy","otherNames":["exposure and response prevention","psychotherapy","counseling"]},{"name":"d-cycloserine","otherNames":[]},{"name":"Pill placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatient youth with obsessive-compulsive disorder between the ages 7-17 years.\n* A Children's Yale-Brown Obsessive-Compulsive Scale score ≥ 16\n* Child has a Full Scale IQ≥85 as assessed on the WASI (within 90% CI).\n* English speaking\n\nExclusion Criteria:\n\n* Receiving concurrent psychotherapy or a past adequate trial of CBT for OCD. Families will have the option of discontinuing such services to enroll in the study.\n* New Treatments: Initiation of an antidepressant within 12 weeks before study enrollment or an antipsychotic 6 weeks before study enrollment. No new alternative medications, nutritionals or therapeutic diets within 6 weeks of study enrollment.\n* Established Treatment changes: Any change in established psychotropic medication (e.g., antidepressants, anxioloytics, stimulant, alpha agonist) within 8 weeks before study enrollment (6 weeks for antipsychotic). Alternative medications must be stable for 6 weeks prior to baseline.\n* Current clinically significant suicidality or individuals who have engaged in suicidal behaviors within 6 months will be excluded.\n* DSM-IV conduct disorder, autism, bipolar, schizophrenia or schizoaffective disorders; or substance abuse in past 6 months using all available information.\n* Youth with hoarding symptoms that are their primary form of OCD.\n* Weight less than 25.0 kg.\n* Epilepsy, renal insufficiency, and current/past history of alcohol abuse.\n* Pregnant or having unprotected sex \\[in females\\] as the effects of d-cycloserine on pregnancy are unknown.\n* Presence of a significant and/or unstable medical illness that might lead to hospitalization during the study.\n* Known d-cycloserine allergy.","healthyVolunteers":true,"sex":"ALL","minimumAge":"7 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Children's Yale-Brown Obsessive-Compulsive Scale.","description":"The Children's Yale-Brown Obsessive-Compulsive Scale measures the severity of OCD symptoms. There are 10 questions that are summed to arrive at a total score, with higher scores representing more severe OCD symptoms (scores range from 0-40).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.53","spread":null},{"groupId":"OG001","value":"13.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Severity","description":"The Clinical Global Impression-Severity involves a trained clinician rating how severe the person's OCD symptoms are on a 0 to 6 scale, with higher scores corresponding to more severe symptoms. This rating only involves a clinician completing a single item.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":null},{"groupId":"OG001","value":"2.28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":72},"commonTop":[]}}}